1. Home
  2. JAGX vs CERO Comparison

JAGX vs CERO Comparison

Compare JAGX & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAGX
  • CERO
  • Stock Information
  • Founded
  • JAGX 2013
  • CERO 2017
  • Country
  • JAGX United States
  • CERO United States
  • Employees
  • JAGX N/A
  • CERO N/A
  • Industry
  • JAGX Biotechnology: Pharmaceutical Preparations
  • CERO
  • Sector
  • JAGX Health Care
  • CERO
  • Exchange
  • JAGX Nasdaq
  • CERO Nasdaq
  • Market Cap
  • JAGX 3.8M
  • CERO 3.1M
  • IPO Year
  • JAGX N/A
  • CERO N/A
  • Fundamental
  • Price
  • JAGX $8.06
  • CERO $1.11
  • Analyst Decision
  • JAGX
  • CERO Strong Buy
  • Analyst Count
  • JAGX 0
  • CERO 1
  • Target Price
  • JAGX N/A
  • CERO $11.00
  • AVG Volume (30 Days)
  • JAGX 66.3K
  • CERO 4.6M
  • Earning Date
  • JAGX 05-13-2025
  • CERO 05-16-2025
  • Dividend Yield
  • JAGX N/A
  • CERO N/A
  • EPS Growth
  • JAGX N/A
  • CERO N/A
  • EPS
  • JAGX N/A
  • CERO N/A
  • Revenue
  • JAGX $11,689,000.00
  • CERO N/A
  • Revenue This Year
  • JAGX $38.22
  • CERO N/A
  • Revenue Next Year
  • JAGX $39.96
  • CERO N/A
  • P/E Ratio
  • JAGX N/A
  • CERO N/A
  • Revenue Growth
  • JAGX 19.75
  • CERO N/A
  • 52 Week Low
  • JAGX $4.02
  • CERO $0.53
  • 52 Week High
  • JAGX $540.00
  • CERO $171.00
  • Technical
  • Relative Strength Index (RSI)
  • JAGX 57.58
  • CERO 60.93
  • Support Level
  • JAGX $5.00
  • CERO $0.53
  • Resistance Level
  • JAGX $6.13
  • CERO $0.84
  • Average True Range (ATR)
  • JAGX 0.87
  • CERO 0.13
  • MACD
  • JAGX 0.72
  • CERO 0.07
  • Stochastic Oscillator
  • JAGX 88.07
  • CERO 65.01

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

Share on Social Networks: